ES2096215T3 - Tucaresol como agente inmunopotenciador. - Google Patents

Tucaresol como agente inmunopotenciador.

Info

Publication number
ES2096215T3
ES2096215T3 ES93307373T ES93307373T ES2096215T3 ES 2096215 T3 ES2096215 T3 ES 2096215T3 ES 93307373 T ES93307373 T ES 93307373T ES 93307373 T ES93307373 T ES 93307373T ES 2096215 T3 ES2096215 T3 ES 2096215T3
Authority
ES
Spain
Prior art keywords
tucaresol
combinations
compound
immunopotentiating agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93307373T
Other languages
English (en)
Inventor
John Richard Rhodes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220715A external-priority patent/GB9220715D0/en
Priority claimed from GB929226874A external-priority patent/GB9226874D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2096215T3 publication Critical patent/ES2096215T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Planar Illumination Modules (AREA)
  • Illuminated Signs And Luminous Advertising (AREA)
  • Securing Globes, Refractors, Reflectors Or The Like (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DEL ACIDO 4-(2-FORMIL-3HIDROXIFENOXIMETIL)BENZOICO O A LAS SALES FISIOLOGICAMENTE ACEPTABLES DEL MISMO COMO AGENTE INMUNOPOTENCIADOR, ASIMISMO SE REFIERE A LAS COMPOSICIONES QUE CONTIENEN DICHO COMPUESTO Y A SU MANUFACTURA, A LAS COMBINACIONES DE DICHO COMPUESTO CON DROGAS ANTITUMORALES O ANTIINFECCIOSAS Y AL USO DE DICHAS COMBINACIONES EN LA PROFILAXIS O EL TRATAMIENTO DE LAS ENFERMEDADES QUE SE DERIVAN DE TUMORES O INFECCIONES.
ES93307373T 1992-10-01 1993-09-17 Tucaresol como agente inmunopotenciador. Expired - Lifetime ES2096215T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929220715A GB9220715D0 (en) 1992-10-01 1992-10-01 Immunopotentiatory agent and physiologically acceptable salts thereof
GB929226874A GB9226874D0 (en) 1992-12-23 1992-12-23 Immunopotentiatory agents and physiologically acceptable salts thereof

Publications (1)

Publication Number Publication Date
ES2096215T3 true ES2096215T3 (es) 1997-03-01

Family

ID=26301715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93307373T Expired - Lifetime ES2096215T3 (es) 1992-10-01 1993-09-17 Tucaresol como agente inmunopotenciador.

Country Status (24)

Country Link
US (1) US5508310A (es)
EP (3) EP0678298A3 (es)
JP (2) JP3717950B2 (es)
KR (1) KR100348775B1 (es)
CN (1) CN1213746C (es)
AT (1) ATE146075T1 (es)
AU (1) AU676491B2 (es)
CA (1) CA2124677C (es)
CZ (1) CZ132794A3 (es)
DE (1) DE69306545T2 (es)
DK (1) DK0609606T3 (es)
ES (1) ES2096215T3 (es)
GR (1) GR3022541T3 (es)
HR (1) HRP931243A2 (es)
HU (1) HUT70482A (es)
IL (1) IL107157A0 (es)
MX (1) MX9306079A (es)
NZ (1) NZ256110A (es)
RU (1) RU94028670A (es)
SG (1) SG48993A1 (es)
SI (1) SI9300514A (es)
SK (1) SK65294A3 (es)
WO (1) WO1994007479A2 (es)
YU (1) YU62793A (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3539795A (en) * 1994-08-25 1996-03-14 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
BR9809149A (pt) * 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ES2245805T3 (es) * 1997-10-03 2006-01-16 Galenica Pharmaceuticals, Inc. Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
GB9818627D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
US6939896B2 (en) * 1999-12-21 2005-09-06 Astrazeneca Ab Cd45 inhibitors
JP2003518085A (ja) * 1999-12-21 2003-06-03 アストラゼネカ アクチボラグ Ｃｄ４５阻害剤
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
AU2001245823A1 (en) * 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
PL211872B1 (pl) 2000-03-31 2012-07-31 Purdue Research Foundation Kompozycja farmaceutyczna
AU2001251491A1 (en) * 2000-04-11 2001-10-23 Galenica Pharmaceuticals, Inc. Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
CA2445826C (en) * 2001-05-02 2014-03-25 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
KR20040053136A (ko) * 2001-09-28 2004-06-23 펄듀 리서치 파운데이션 리간드-면역원 공액체를 이용한 치료 방법
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) * 2002-01-04 2003-08-21 Bryan Fuller Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2004028470A2 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
EP1622554A4 (en) * 2003-05-15 2008-01-02 Bioform Medical Inc COMPOSITIONS CONTAINING A COMBINATION OF A PHARMACEUTICAL AGENT OR A COSMETIC AGENT AND AN OXY-GROUP-WEARING AROMATIC ALDEHYDE
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
JP5554713B2 (ja) * 2007-11-15 2014-07-23 エンドサイト，インク． 接合体を投与する方法
EP2661264B1 (en) 2011-01-07 2018-12-05 Allergan, Inc. Melanin modification compositions and methods of use
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54126731A (en) * 1978-03-20 1979-10-02 Rikagaku Kenkyusho Carcinostatic agent
JPS5545658A (en) * 1978-09-28 1980-03-31 Rikagaku Kenkyusho Carcinostatic agent
JPS5569510A (en) * 1978-11-16 1980-05-26 Mitsubishi Chem Ind Ltd Carcinostatic agent
IT1193786B (it) * 1980-12-18 1988-08-24 Wellcome Found Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione
LU85365A1 (de) * 1984-05-16 1986-01-29 Chimicasa Gmbh Verfahren und praeparat zur stimulierung des immunsystems
DE3431236A1 (de) * 1984-08-24 1986-02-27 Carnivora-Deutschland GmbH, 7109 Jagsthausen Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
DE3528709A1 (de) * 1985-08-09 1987-02-19 Schleicher Peter Mundpflegemittel
JPS63264409A (ja) * 1988-01-13 1988-11-01 Rikagaku Kenkyusho 制癌剤
JPH03254007A (ja) * 1990-03-01 1991-11-13 Tir Syst Ltd 非吸収性で且つ透過率が可変のカバーを有した照明装置
GB9018061D0 (en) * 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
EP0499015A1 (en) * 1991-02-15 1992-08-19 Fockerman, Jasmine Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents

Also Published As

Publication number Publication date
GR3022541T3 (en) 1997-05-31
JP3717950B2 (ja) 2005-11-16
DE69306545D1 (de) 1997-01-23
CA2124677A1 (en) 1994-04-14
US5508310A (en) 1996-04-16
NZ256110A (en) 1997-07-27
DE69306545T2 (de) 1997-04-03
EP0614357A1 (en) 1994-09-14
RU94028670A (ru) 1996-05-20
WO1994007479A3 (en) 1994-07-21
CN1213746C (zh) 2005-08-10
EP0678298A3 (en) 1996-05-29
CZ132794A3 (en) 1995-02-15
DK0609606T3 (es) 1997-03-17
MX9306079A (es) 1994-06-30
AU4831193A (en) 1994-04-26
YU62793A (sh) 1998-05-15
SG48993A1 (en) 1998-05-18
WO1994007479A2 (en) 1994-04-14
EP0678298A2 (en) 1995-10-25
JPH072660A (ja) 1995-01-06
HRP931243A2 (en) 1995-12-31
AU676491B2 (en) 1997-03-13
IL107157A0 (en) 1993-12-28
EP0609606B1 (en) 1996-12-11
HUT70482A (en) 1995-10-30
EP0609606A1 (en) 1994-08-10
CN1091005A (zh) 1994-08-24
SK65294A3 (en) 1995-03-08
CA2124677C (en) 2008-09-09
HU9401631D0 (en) 1994-08-29
JPH07504204A (ja) 1995-05-11
SI9300514A (en) 1994-06-30
KR100348775B1 (ko) 2003-02-11
ATE146075T1 (de) 1996-12-15

Similar Documents

Publication Publication Date Title
ES2096215T3 (es) Tucaresol como agente inmunopotenciador.
ITMI911299A1 (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
DE69933208D1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
GR3026218T3 (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro derivatives of alpha D-neuraminic acid
ES2092539T3 (es) Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
NO924066D0 (no) Terapeutisk middel
ATE340561T1 (de) Verwendung von antiseptika zur herstellung von arzneimitteln zur prophylaxe und behandlung von entzündungen im korperinneren des menschen
DE60025503D1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
ES2169272T3 (es) Diaminopirimidinas, composiciones farmaceuticas que las contienen y su utilizacion como agente antibacteriano.
NO912414D0 (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
SE8600658D0 (sv) Novel composition of matter
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
DK347289D0 (da) Terapeutiske forbindelser
SE9901572D0 (sv) New compounds
FI923662A0 (fi) Terapeutiska medel.
AR034012A1 (es) Compuestos peptidicos, las composiciones farmaceuticas que las contienen y el uso de las mismas para la preparacion de medicamentos
AU4519189A (en) Medicaments for the treatment of toxoplasmosis
AR030945A1 (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
MX9203900A (es) Composicion farmaceutica que comprende derivados de acido benzimidazolin-2-oxo-1-carboxilico.
BR0012192A (pt) Derivado de ácido quinolinocarboxìlico ou seus sais
MC2203A1 (fr) Medicament contre la cryptosporidiose

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 609606

Country of ref document: ES